Segall Bryant & Hamill LLC Boosts Stock Holdings in Insulet Co. (NASDAQ:PODD)

Segall Bryant & Hamill LLC boosted its stake in Insulet Co. (NASDAQ:PODD - Free Report) by 33.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,052 shares of the medical instruments supplier's stock after purchasing an additional 15,683 shares during the period. Segall Bryant & Hamill LLC owned about 0.09% of Insulet worth $14,675,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. QRG Capital Management Inc. bought a new stake in Insulet during the 3rd quarter worth $297,000. Diversified Trust Co raised its holdings in Insulet by 90.9% in the 2nd quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier's stock valued at $1,842,000 after buying an additional 4,348 shares during the last quarter. Natixis bought a new position in Insulet in the 1st quarter valued at approximately $3,610,000. Linden Thomas Advisory Services LLC boosted its position in Insulet by 65.8% during the 2nd quarter. Linden Thomas Advisory Services LLC now owns 8,812 shares of the medical instruments supplier's stock worth $1,778,000 after buying an additional 3,497 shares during the period. Finally, Assenagon Asset Management S.A. grew its holdings in Insulet by 38.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 179,393 shares of the medical instruments supplier's stock worth $36,202,000 after acquiring an additional 50,101 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PODD shares. Citigroup raised their price target on shares of Insulet from $250.00 to $275.00 and gave the company a "buy" rating in a research note on Tuesday, October 1st. UBS Group raised their target price on Insulet from $211.00 to $223.00 and gave the stock a "neutral" rating in a research report on Friday, August 9th. Morgan Stanley upped their price target on Insulet from $234.00 to $317.00 and gave the company an "overweight" rating in a research report on Monday, November 11th. Raymond James raised their price objective on Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a research report on Monday, October 14th. Finally, BTIG Research upped their target price on Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $253.27.

Insulet Stock Up 1.8 %

PODD stock opened at $266.58 on Thursday. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $279.40. The stock has a market cap of $18.70 billion, a P/E ratio of 45.65, a P/E/G ratio of 4.01 and a beta of 1.22. The stock's fifty day simple moving average is $240.09 and its two-hundred day simple moving average is $209.62. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.